Erika Pagani, country manager for Pfizer Singapore, shares her journey with the company from Brazil to New York, Peru, Ecuador, and finally Singapore. She discusses why the island city-state is well-positioned as a launchpad for Pfizer’s innovation and the “laboratory” for emerging Asia, and how the company is working to win the digital race, changing its go-to-market model.
Singapore is often the first market for [Pfizer's] product launches in Emerging Asia, new regulatory strategies to optimize launch timelines, and digital innovations. We act as something of a laboratory for the region
